Señales en vivo de 9969.HK | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 abr 2024 @ 04:08):

InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases...

Stats
Volumen de hoy	2.93M
Volumen promedio	3.52M
Capitalización de mercado	6.76B
EPS	HKD0 ( 2022-03-22 )
Last Dividend	HKD0 ( N/A )
Next Dividend	HKD0 ( N/A )
P/E	-11.27
ATR14	HKD0.00500 (0.11%)

Volumen Correlación

Largo: 0.03 (neutral)

Corto: -0.92 (very strong negative)

Signal:(35.002) Neutral

InnoCare Pharma Ltd Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

InnoCare Pharma Ltd Correlación - Moneda/Commodity

-0.70
( moderate negative )

-0.59
( weak negative )

0.00
( neutral )

-0.60
( weak negative )

0.66
( moderate )

0.80
( strong )

InnoCare Pharma Ltd Finanzas

Annual	2023
Ingresos:	HKD738.54M
Beneficio Bruto:	HKD610.10M (82.61 %)
EPS:	HKD-0.370

FY	2023
Ingresos:	HKD738.54M
Beneficio Bruto:	HKD610.10M (82.61 %)
EPS:	HKD-0.370

FY	2022
Ingresos:	HKD625.40M
Beneficio Bruto:	HKD482.01M (77.07 %)
EPS:	HKD-0.590

FY	2021
Ingresos:	HKD1.04B
Beneficio Bruto:	HKD977.37M (93.70 %)
EPS:	HKD-0.0500

Financial Reports:

No articles found.

InnoCare Pharma Ltd

InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases. It develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom's macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. The company is also developing ICP-192, a pan-FGFR inhibitor that is in a Phase I/II clinical trial for the treatment of solid tumor patients, including cholangiocarcinoma, and head and neck cancer; ICP-723, a pan-TRK inhibitor, which is in Phase I clinical trial to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-332, a novel tyrosine kinase 2 inhibitor that is in a Phase I clinical trial for the treatment of autoimmune diseases; and ICP-B02, a bispecific antibody for the treatment of lymphoma. In addition, it develops ICP-189, ICP-915, and ICP-B03 for the treatment of solid tumors; ICP-033 to treat liver cancer, renal cell carcinoma, colorectal cancer, and other solid tumors; ICP-488 for the treatment of autoimmune diseases; ICP-B05, an anti-CC chemokine receptor 8 monoclonal antibody for the treatment of various cancers; ICP-248 to treat hematology; and ICP-490 for the treatment of hematology and autoimmune diseases. Further, it offers ICP-B04 (Tafasitamab) to treat DLBCL/hematology. InnoCare Pharma Limited was incorporated in 2015 and is headquartered in Beijing, China.